Community 365 Roundtable Meeting: 2023 - A Year of Opportunities on Pharmaceutical Access and Value

We're pleased to invite you to the Community 365 Roundtable Meeting: 2023 - Year of Opportunities on Pharmaceutical Access and Value which aims to address the upcoming revisions to the EU Pharmaceutical Regulations and what it means for cancer, as well as discuss the application of the EU's HTA Regulation and its relevance to cancer.

Join Co-Chairs Matti Aapro, ECO Immediate Past-President, and Mirjam Crul, ECO Board Member and Co-Chair of both our Special Network on the Impact of Covid-19 on Cancer and our Workforce Network, on 27 February from 16:00-18:30 CET.


Take the Survey Button

27 February 2023 16:00 - 18:30 CET

Virtual

 Apply for Registration

View the Recording from the Roundtable meeting here.

Download the Action Report from the Roundtable meeting here.

 

This is an Inequalities Network related event and also supported by our National & European Parliamentarians for Cancer Action group:

ineqv2 Parliamentarians for Cancer Action Logo.1


Programme

16:00-16:10: Welcome and introductions

16:10-16:17: A Political View on the EU Pharmaceutical Legislation

16:17-17:10: Part 1 - The Upcoming Revisions to the EU Pharmaceutical Regulations and What it Means for Cancer

16:17-16:30 - Current Status of the Pharmaceutical Regulations update & Providing Relevant Background

  • Matti Aapro, Past-President, European Cancer Organisation 
  • Mirjam Crul, Board Member and Co-Chair of both Special Network on the Impact of Covid-19 on Cancer and Workforce Network, European Cancer Organisation 
  • Richard Price, Head of Policy, European Cancer Organisation 
16:30-17:05: Unmet Medical Need - How to Better Define? How Might the Cancer Sector Benefit?

  • Kostas Stamatopoulos, Member, Research and European Affairs Committees, European Hematology Association
  • Jean-Pierre Delord, Head Clinical Research Unit, Medical Oncology Dept, Toulouse-Oncopole
  • Antonella Cardone, Patient Advocacy Expert and Advisor to the Board of Pancreatic Cancer Europe
  • Marcus Hollenbach, Councillor of Clinical Science, European Pancreatic Club 
  • Lydie Meheus, Managing Director, Anticancer Fund

  • Nicholas Cosenza, Senior Manager Government Affairs, Amgen

17:05-17:10: Summary and Conclusions from the Discussion


17:10-17:50: Part 2 - The Opportunities for Addressing Medicines Shortages in 2023

17:10-17:25: Setting the Scene - The Shortages Situation We Face

  • Mirjam Crul, Vice-President, EU and European Affairs, European Society of Oncology Pharmacy 
17:25-17:35: The EMA’s New Role on Medicines Shortages

  • Monica Dias, Head of Supply and Availability of Medicines and Medical Devices, European Medicines Agency
17:35-17:45: Exchange on Next Steps

  • Despoina Makridaki, Director of Professional Development, European Association of Hospital Pharmacists (EAHP) 
  • Romilda Baldacchino Zarb MP, Pharmacist, and Member, Parliamentarians for Cancer Action, Malta
  • François Houÿez, Information & Access to Therapies Director & Health Policy Advisor, Eurordis
  • Charles Faid, Director, Global Trade Policy & Public Affairs, Pfizer
17:45-17:50: Summary and Conclusions from the Discussion


17:50-18:25: Part 3 - The Application of the EU’s HTA Regulation and its Relevance to Cancer 

17:50-18:00: What is the EU HTA Regulation and How is the Progress of the Regulation so far?
 
  • Roisin Adams, Head of HTA Strategy and Chair of the HTA Regulation Coordination Group, National Centre for Pharmacoeconomics, Ireland
18:00-18:25: Exchange and Discussion on the HTA Regulation and What it Means for Cancer 

  • Robin Doeswijk, Head of European Affairs, European Hematology Association
  • Claudia Furtado, Head of the Health Technology Assessment, Pricing and Reimbursement Division (DATS) as well of the Information and Strategic Planning Division (DIPE), INFARMED
  • Anne-Pierre Pickaert, Specialist on HTA and patient access, Patvocates
  • Brian Cuffel, Vice President and Market Access Head, Oncology at Bayer Pharmaceuticals

18:25-18:30: Part 4 - Conclusions

Speakers

  • Tomislav Sokol MEP MEMBER, SPECIAL COMMITTEE ON THE COVID-19 PANDEMIC (COVI), and Member, Parliamentarians for Cancer Action, Croatia
  • Romilda Baldacchino Zarb MP Pharmacist, and Member, Parliamentarians for Cancer Action, Malta
  • Matti Aapro Immediate Past-President, European Cancer Organisation
  • Mirjam Crul Board Member and Co-Chair of both the Special Network on the Impact of Covid-19 on Cancer and Workforce Network, European Cancer Organisation
  • Kostas Stamatopoulos Member, Research and European Affairs Committees, European Hematology Association
  • Despoina Makridaki Director, Professional Development, European Association of Hospital Pharmacists (EAHP)
show all speakers (21)

Speakers

  • Tomislav Sokol MEP MEMBER, SPECIAL COMMITTEE ON THE COVID-19 PANDEMIC (COVI), and Member, Parliamentarians for Cancer Action, Croatia
  • Romilda Baldacchino Zarb MP Pharmacist, and Member, Parliamentarians for Cancer Action, Malta
  • Matti Aapro Immediate Past-President, European Cancer Organisation
  • Mirjam Crul Board Member and Co-Chair of both the Special Network on the Impact of Covid-19 on Cancer and Workforce Network, European Cancer Organisation
  • Kostas Stamatopoulos Member, Research and European Affairs Committees, European Hematology Association
  • Despoina Makridaki Director, Professional Development, European Association of Hospital Pharmacists (EAHP)
show all speakers (21)
  • Tomislav Sokol MEP MEMBER, SPECIAL COMMITTEE ON THE COVID-19 PANDEMIC (COVI), and Member, Parliamentarians for Cancer Action, Croatia Read Bio
  • Romilda Baldacchino Zarb MP Pharmacist, and Member, Parliamentarians for Cancer Action, Malta
  • Matti Aapro Immediate Past-President, European Cancer Organisation
  • Mirjam Crul Board Member and Co-Chair of both the Special Network on the Impact of Covid-19 on Cancer and Workforce Network, European Cancer Organisation
  • Kostas Stamatopoulos Member, Research and European Affairs Committees, European Hematology Association Read Bio
  • Despoina Makridaki Director, Professional Development, European Association of Hospital Pharmacists (EAHP) Read Bio
  • Roisin Adams Roisin Adams, Head of HTA Strategy and Chair of the HTA Regulation Coordination Group, National Centre for Pharmacoeconomics, Ireland
  • Robin Doeswijk Head of European Affairs, European Hematology Association Read Bio
  • Jean-Pierre Delord Head Clinical Research Unit, Medical Oncology Dept, Toulouse-Oncopole Read Bio
  • Marcus Hollenbach Councillor of Clinical Science, European Pancreatic Club
  • Anne-Pierre Pickaert Specialist on HTA and Patient Access, Patvocates Read Bio
  • Antonella Cardone Patient Advocacy Expert and Advisor to the Board of Pancreatic Cancer Europe
  • Monica Dias Head of Supply and Availability of Medicines and Medical Devices, European Medicines Agency
  • Lydie Meheus Managing Director, Anticancer Fund Read Bio
  • François Houÿez Information & Access to Therapies Director & Health Policy Advisor, Eurordis
  • Claudia Furtado Head of the Health Technology Assessment, Pricing and Reimbursement Division (DATS) as well of the Information and Strategic Planning Division (DIPE), INFARMED
  • Nicholas Cosenza Senior Manager Government Affairs, Amgen
  • Brian Cuffel Vice President and Market Access Head, Oncology at Bayer Pharmaceuticals
  • Charles Faid Director of Global Trade Policy & Public Affairs, Pfizer Read Bio
  • Richard Price Head of Policy, European Cancer Organisation
  • Norbert Couespel Policy and Research Officer, European Cancer Organisation

Speakers

  • Tomislav Sokol MEP MEMBER, SPECIAL COMMITTEE ON THE COVID-19 PANDEMIC (COVI), and Member, Parliamentarians for Cancer Action, Croatia
  • Romilda Baldacchino Zarb MP Pharmacist, and Member, Parliamentarians for Cancer Action, Malta
  • Matti Aapro Immediate Past-President, European Cancer Organisation
  • Mirjam Crul Board Member and Co-Chair of both the Special Network on the Impact of Covid-19 on Cancer and Workforce Network, European Cancer Organisation
  • Kostas Stamatopoulos Member, Research and European Affairs Committees, European Hematology Association
  • Despoina Makridaki Director, Professional Development, European Association of Hospital Pharmacists (EAHP)
show all speakers (21)

Speakers

  • Tomislav Sokol MEP MEMBER, SPECIAL COMMITTEE ON THE COVID-19 PANDEMIC (COVI), and Member, Parliamentarians for Cancer Action, Croatia
  • Romilda Baldacchino Zarb MP Pharmacist, and Member, Parliamentarians for Cancer Action, Malta
  • Matti Aapro Immediate Past-President, European Cancer Organisation
  • Mirjam Crul Board Member and Co-Chair of both the Special Network on the Impact of Covid-19 on Cancer and Workforce Network, European Cancer Organisation
  • Kostas Stamatopoulos Member, Research and European Affairs Committees, European Hematology Association
  • Despoina Makridaki Director, Professional Development, European Association of Hospital Pharmacists (EAHP)
show all speakers (21)